Dong-A ST Signs Professional Sales Agreement with i-SENS for Continuous Glucose Monitor "CareSens Air"

Domestic Distribution and Sales Activities for Hospitals and Clinics

Dong-A ST announced on October 21 that it has signed a contract with i-SENS for the professional sales of the continuous glucose monitoring device "CareSens Air" at its headquarters in Yongdu-dong, Dongdaemun-gu, Seoul.

This agreement was concluded to combine Dong-A ST's hospital and medical institution sales network with i-SENS's blood glucose monitoring technology, aiming to provide more precise and efficient blood glucose management solutions in clinical settings.

At the contract signing ceremony for the sale of the continuous glucose monitor "CareSens Air" for professionals between Dong-A ST and i-SENS, Jaehoon Jung, President of Dong-A ST (right), and Geunsik Cha, CEO of i-SENS, are taking a commemorative photo. Dong-A ST

Under the agreement, i-SENS will supply the professional version of CareSens Air to Dong-A ST. Dong-A ST will distribute the professional version of CareSens Air to domestic hospitals and clinics, and will carry out sales and marketing activities.

i-SENS is a specialized manufacturer of diagnostic medical devices, including self-monitoring blood glucose meters, continuous glucose monitoring devices, and glycated hemoglobin analyzers. Through the "CareSens" brand and various ODM businesses, the company has secured the largest market share in the blood glucose meter sector in Korea, and exports its products to more than 110 countries, including the United States, Japan, and Europe.

The continuous glucose monitoring device CareSens Air attaches a sensor to the skin, allowing for continuous, blood-free glucose monitoring for up to 15 days, 24 hours a day. The measured data can be shared and managed in real time by medical staff, patients, and caregivers through a smartphone app, providing real-time insights into blood glucose trends and patterns that are difficult to capture with conventional self-monitoring blood glucose meters or glycated hemoglobin tests.

The hospital and clinic-exclusive CareSens Air professional version is a domestic continuous glucose monitoring device that is eligible for reimbursement for test result interpretation even in cases of type 2 diabetes, addressing the non-reimbursable limitations of existing personal continuous glucose monitoring devices. Personal continuous glucose monitoring devices allow patients to check their own blood glucose, which can result in temporary behavioral changes and potentially inaccurate blood glucose fluctuations. In contrast, the professional continuous glucose monitoring device is designed to restrict blood glucose checking by the patient, enabling the collection of undistorted, real-life blood glucose patterns during daily activities. This allows medical professionals to more accurately analyze blood glucose fluctuations based on patients' actual lifestyle habits and to develop tailored treatment strategies.

Geunsik Cha, Chairman of i-SENS, stated, "This agreement will serve as a turning point, leveraging i-SENS's proprietary continuous glucose monitoring technology and Dong-A ST's robust hospital and clinic network to provide more precise and efficient blood glucose management solutions in clinical settings. i-SENS will continue to set new standards for diabetes management both domestically and internationally through ongoing technological innovation and global market expansion."

Jaehoon Jung, President of Dong-A ST, said, "The continuous glucose monitoring device market is rapidly growing both domestically and internationally, and the CareSens Air professional version is attracting significant attention in clinical settings. By strengthening our collaboration with i-SENS, we aim to expand the adoption of continuous glucose monitoring devices and contribute to improving patients' quality of life."

This content was produced with the assistance of AI translation services.